NIKKEI 225
38,692.78 -410.44 (-1.05%) HANG SENG
18,623.85 -244.86 (-1.30%) CRUDE OIL
76.80 -0.07 (-0.09%) GOLD FUTURES
2,336.60 -0.60 (-0.03%) DOW
39,065.26 -605.78 (-1.53%) Bitcoin GBP
52,946.69 -1,710.05 (-3.13%)
Intelligent Bio Solutions Inc. (INBS)
After hours:
| Previous close | 2.4100 |
| Open | 2.4700 |
| Bid | 2.2700 x 200 |
| Ask | 2.3400 x 200 |
| Day's range | 2.2600 - 2.4700 |
| 52-week range | 2.1600 - 44.8800 |
| Volume | |
| Avg. volume | 89,671 |
| Market cap | 7.512M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -29.5600 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.00 |
GlobeNewswireIntelligent Bio Solutions Unveils Key Performance Indicator Growth in the United Kingdom as Drug Screening Industry Combats Drug Test Cheating and Searches for Simpler, Faster, Non-Invasive and More Cost-Effective Solutions
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today unveiled key performance indicators from its United Kingdom operations. These indicators have contributed to the Company’s growth as the drug screening industry continues to combat drug test cheating and searches for simpler, faster, non-invasive, and more cost-effective solutions. For
- GlobeNewswire
Innovative Fingerprint Drug Screening Solution Showcased at the UK's Premier Health and Safety Event
NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful exhibition of its Intelligent Fingerprinting Drug Screening Solution at The Health & Safety Event 2024, the United Kingdom’s largest annual technology showcase exhibiting products and services that strengthen and support workplace safety standards. According to
- GlobeNewswire
Intelligent Bio Solutions Inc. Reports Fiscal 2024 Third Quarter and Nine-Month Financial Results and Operational Highlights
Year-over-year revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024 Cash and cash equivalents as of March 31, 2024, was $9.40 million Commenced FDA 510(k) clinical studies plan with Cliantha Research and remains on track for planned submission by the end of 2024 and planned entry into the US in 2025 Secured 26 new customer accounts throughout the quarter, representing a combined headcount of approximately 16,779 employees NEW YORK, May 08, 2024 (GL
